Virbac SA (FRA:V16)

Market Cap	2.93B -2.3%
Revenue (ttm)	1.49B +4.3%
Net Income	155.85M +17.2%
EPS	18.58 +17.0%
Shares Out	n/a
PE Ratio	18.51
Forward PE	16.43
Dividend	1.45 (0.42%)
Ex-Dividend Date	Jul 2, 2026

Volume	n/a
Open	347.00
Previous Close	345.50
Day's Range	344.00 - 347.00
52-Week Range	296.00 - 381.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 30, 2026

About Virbac

Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric ph...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1968
• Employees: 6,442
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: V16

Financial Performance

In 2025, Virbac's revenue was 1.46 billion, an increase of 4.82% compared to the previous year's 1.40 billion. Earnings were 150.89 million, an increase of 3.85%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 24, 2026

Data Sources Report a data error